Cover Image
市場調查報告書

Celsion Corporation - 產品平台分析

Celsion Corporation - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253760
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
Celsion Corporation - 產品平台分析 Celsion Corporation - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 49 Pages
簡介

Celsion Corporation是總公司設立於美國的生物製藥企業,著重於創新的癌症治療藥之開發與商品化。正在開發集中熱活性型藥物遞送系統和熱能的新腫瘤標靶藥物。

本報告提供Celsion Corporation的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Celsion Corporation的基本資料

  • Celsion Corporation概要
  • 主要資訊
  • 企業資料

Celsion Corporation:R&D概要

  • 主要的治療範圍

Celsion Corporation:開發平台分析

  • 各開發階段的開發中產品
  • 單劑產品

Celsion Corporation:開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅱ相的產品/聯合治療模式
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Celsion Corporation:藥物簡介

  • doxorubicin liposomal
  • EGEN-001
  • carboplatin liposomal
  • docetaxel liposomal
  • EGEN-002
  • Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension

Celsion Corporation:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Celsion Corporation:最近的開發平台資訊

Celsion Corporation:暫停開發中的計劃

Celsion Corporation:開發中止的開發中產品

Celsion Corporation:企業理念

Celsion Corporation:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07107CDB

Summary

Global Markets Direct's, 'Celsion Corporation - Product Pipeline Review - 2015', provides an overview of the Celsion Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celsion Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Celsion Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Celsion Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Celsion Corporation's pipeline products

Reasons to buy

  • Evaluate Celsion Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Celsion Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Celsion Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Celsion Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celsion Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Celsion Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Celsion Corporation Snapshot
    • Celsion Corporation Overview
    • Key Information
    • Key Facts
  • Celsion Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Celsion Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Celsion Corporation - Pipeline Products Glance
    • Celsion Corporation - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Celsion Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Celsion Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Celsion Corporation - Drug Profiles
    • doxorubicin liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EGEN-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • carboplatin liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • docetaxel liposomal
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EGEN-002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Celsion Corporation - Pipeline Analysis
    • Celsion Corporation - Pipeline Products by Target
    • Celsion Corporation - Pipeline Products by Route of Administration
    • Celsion Corporation - Pipeline Products by Molecule Type
    • Celsion Corporation - Pipeline Products by Mechanism of Action
  • Celsion Corporation - Recent Pipeline Updates
  • Celsion Corporation - Dormant Projects
  • Celsion Corporation - Company Statement
  • Celsion Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Celsion Corporation, Key Information
  • Celsion Corporation, Key Facts
  • Celsion Corporation - Pipeline by Indication, 2015
  • Celsion Corporation - Pipeline by Stage of Development, 2015
  • Celsion Corporation - Monotherapy Products in Pipeline, 2015
  • Celsion Corporation - Phase III, 2015
  • Celsion Corporation - Phase II, 2015
  • Celsion Corporation - Phase I, 2015
  • Celsion Corporation - Preclinical, 2015
  • Celsion Corporation - Pipeline by Target, 2015
  • Celsion Corporation - Pipeline by Route of Administration, 2015
  • Celsion Corporation - Pipeline by Molecule Type, 2015
  • Celsion Corporation - Pipeline Products by Mechanism of Action, 2015
  • Celsion Corporation - Recent Pipeline Updates, 2015
  • Celsion Corporation - Dormant Developmental Projects,2015
  • Celsion Corporation, Subsidiaries

List of Figures

  • Celsion Corporation - Pipeline by Top 10 Indication, 2015
  • Celsion Corporation - Pipeline by Stage of Development, 2015
  • Celsion Corporation - Monotherapy Products in Pipeline, 2015
  • Celsion Corporation - Pipeline by Top 10 Target, 2015
  • Celsion Corporation - Pipeline by Top 10 Route of Administration, 2015
  • Celsion Corporation - Pipeline by Top 10 Molecule Type, 2015
  • Celsion Corporation - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top